ARTICLE | Clinical News
Olodaterol/tiotropium: Phase III started
February 9, 2015 8:00 AM UTC
Boehringer Ingelheim began the double-blind, international Phase III DYNAGITO trial to compare 5/5 µg inhaled olodaterol/tiotropium once daily vs. Boehringer’s 5 µg Spiriva Respimat tiotropium once d...